Time-dependent clearance of mycophenolic acid in renal transplant recipients

British Journal of Clinical Pharmacology

Volumn 63, Issue 6, 2007, Pages 741-752

  Van Hest, Reinier M ^a   Van Gelder, Teun ^a   Bouw, René ^b   Goggin, Timothy ^c   Gordon, Robert ^d   Mamelok, Richard D ^e   Mathot, Ron A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ROCHE PRODUCTS LTD   (United Kingdom)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

^d HOFFMANN LA ROCHE INC   (United States)

^e Mamelok Consulting   (United States)

Author keywords

Mycophenolic acid; Pharmacokinetics; Renal transplantation; Time dependent clearance

Indexed keywords

ALBUMIN; ANTACID AGENT; ANTIVIRUS AGENT; CORTICOSTEROID; CREATININE; CYCLOSPORIN; DACLIZUMAB; HEMOGLOBIN; HISTAMINE H2 RECEPTOR ANTAGONIST; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; COMPARTMENT MODEL; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG ABSORPTION; DRUG CLEARANCE; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; STATISTICAL MODEL; SURGICAL PATIENT;

ADOLESCENT; ADULT; AGED; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; MYCOPHENOLIC ACID; TIME FACTORS;

EID: 34248575629     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2006.02841.x     Document Type: Article

References (42)

1. Bullingham RES, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet 1998 34 : 429 55.
2. Shaw LM, Korecka M, Venkataramanan R, Goldberg L, Bloom R, Brayman KL. Mycophenolic acid pharmacodynamics and pharmacokinetics provide a basis for rational monitoring strategies. Am J Transplant 2003 3 : 534 42.
3. Hale MD, Nicholls AJ, Bullingham RE, Hene R, Hoitsma A, Squifflet JP, Weimar W, Vanrenterghem Y, Van de Woude FJ, Verpooten GA. The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Clin Pharmacol Ther 1998 64 : 672 83.
4. Van Gelder T, Hilbrands LB, Vanrenterghem Y, Weimar W, de Fijter JW, Squifflet JP, Hene RJ, Verpooten GA, Navarro MT, Hale MD, Nicholls AJ. A randomized double blind, multicenter plasma concentration study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation 1999 68 : 261 6.
5. Weber LT, Shipkova M, Armstrong VW, Wagner N, Schutz E, Mehls O, Zimmerhackl LB, Oellerich M, Tonshoff B. The pharmacokinetic-pharmacodynamic relationship for total and free mycophenolic acid in pediatric renal transplant recipients: a report from the German Study Group on mycophenolate mofetil therapy. J Am Soc Nephrol 2002 13 : 759 68.
6. Kuypers DR, Claes K, Evenepoel P, Maes B, Vanrenterghem Y. Clinical efficacy and toxicity profile of tacrolimus and mycophenolic acid in relation to combined long-term pharmacokinetics in de novo renal allograft recipients. Clin Pharmacol Ther 2004 75 : 434 47.
7. Kuypers DRJ, Vanrenterghem Y, Squifflet JP, Mourad M, Abramowicz D, Oellerich M, Armstrong V, Shipkova M, Daems J. Twelve-month evaluation of the clinical pharmacokinetics of total and free mycophenolic acid and its glucuronide metabolite in renal transplant recipients on low dose tacrolimus in combination with mycophenolate mofetil. Ther Drug Monit 2003 25 : 609 22.
8. Shaw LM, Holt DW, Oellerich M, Meiser B, Van Gelder T. Current issues in therapeutic drug monitoring of mycophenolic acid: report of a roundtable discussion. Ther Drug Monit 2001 23 : 305 15.
9. Weber LT, Shipkova M, Lamersdorf T, Niedmann PD, Wiesel M, Mandelbaum A, Zimmerhackl LB, Schutz E, Mehls O, Oellerich M, Armstrong VW, Tonshoff B. Pharmacokinetics of mycophenolic acid (MPA) and determinants of MPA free fraction in pediatric and adult renal transplant recipients. J Am Soc Nephrol 1998 9 : 1511 20.
10. Shaw LM, Korecka M, Aradhye S, Grossman R, Bayer L, Innes C, Cucciara A, Barker C, Naji A, Nicholls A, Brayman K. Mycophenolic acid area under the curve values in African American and Caucasian renal transplant patients are comparable. J Clin Pharmacol 2000 40 : 624 33.
11. Kuypers DR, Claes K, Evenepoel P, Maes B, Coosemans W, Pirenne J, Vanrenterghem Y. Long-term changes in mycophenolic acid exposure in combination with tacrolimus and corticosteroids are dose dependent and not reflected by trough plasma concentration. A prospective study in 100 de novo renal allograft recipients. J Clin Pharmacol 2003 43 : 866 80.
12. Büchler M, Lebranchu Y, Bénéton M, Le Meur Y, Heng AE, Westeel PF, Le Guellec C, Libert F, Hary L, Marquet P, Paintaud G. Higher exposure to mycophenolic acid with sirolimus than with cyclosporine cotreatment. Clin Pharmacol Ther 2005 78 : 34 42.
13. Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. US Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 1995 60 : 225 32.
14. The US Mycophenolate Mofetil Study Group. Mycophenolate mofetil for the prevention of acute rejection of primary cadaveric kidney transplants: status of the MYC 1866 study at 1 year. Transplant Proc 1997 29 : 348 9.
15. Ekberg H, Grinyo J, Nashan B, Vanrenterghem Y, Vincenti F, Calleja E, Nasmyth-Miller C, Truman M, on behalf of the CAESAR Study Group. The use of daclizumab and mycophenolate mofetil in combination with corticosteroids and cyclosporine (low dose versus low dose followed by withdrawal) to optimize renal function in recipients of renal allografts. Transplantation 2004 78 (Suppl 458 9.
16. Pescovitz MD, Guasch A, Gaston R, Rajagopalan P, Tomlanovich S, Weinstein S, Bumgardner GL, Melton L, Ducray PS, Banken L, Hall J, Boutouyrie BX. Equivalent pharmacokinetics of mycophenolate mofetil in African-American and Caucasian male and female stable renal allograft recipients. Am J Transplant 2003 3 : 1581 6.
17. United States Food and Drug Administration. Guidance for Industry: Bioanalytical Method Validation 2001.
18. Tsina I, Chu F, Hama K, Kaloostian M, Tam YL, Tarnowski T, Wong B. Manual and automated (robotic) high-performance liquid chromatography methods for the determination of mycophenolic acid and its glucuronide conjugate in human plasma. J Chrom B Biomed Appl 1996 675 : 119 29.
19. Karlsson MO, Sheiner LB. The importance of modeling interoccasion variabililty in population pharmacokinetic analyses. J Pharmacokinet Biopharm 1993 21 : 735 50.
20. Sheiner LB, Beal SL. Evaluation of methods for estimating population pharmacokinetic parameters. III. Monoexponential model: routine clinical pharmacokinetic data. J Pharmacokinet Biopharm 1983 11 : 303 19.
21. Beal SL, Sheiner LB. NONMEM User's Guides, NONMEM Project Group. University of California at San Francisco, San Francisco, 1998.
22. Wahlby U, Thomson AH, Milligan PA, Karlsson MA. Models for time-varying covariates in population pharmacokinetic-pharmacodynamic analysis. Br J Clin Pharmacol 2004 58 : 367 77.
23. Ette E, Ludden T. Population pharmacokinetic modeling: the importance of informative graphics. Pharm Res 1995 12 : 1845 55.
24. Jonsson EN, Karlsson MO. Xpose and S-PLUS based model building aid for population analysis with NONMEM. In : The population approach: Measuring and managing variability in response, concentration and dose, eds. Aarons L, Balant LP, Danhof, M. Brussels, European Commission, 1997.
25. Ette EI. Stability and performance of a population pharmacokinetic model. J Clin Pharmacol 1997 37 : 486 95.
26. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976 16 : 31 41.
27. Poge U, Gerhardt T, Palmedo H, Klehr HU, Sauerbruch T, Woitas RP. MDRD equations for estimation of GFR in renal transplant recipients. Am J Transplant 2005 June 5 : 1306 11.
28. Nowak I, Shaw LM. Mycophenolic acid binding to serum albumin: characterization and relation to pharmacodynamics. Clin Chem 1995 41 : 1011 7.
29. Kaplan B, Meier-Kriesche HU, Friedman G, Mulgaonkar S, Gruber S, Korecka M, Brayman KL, Shaw LM. The effect of renal insufficiency on mycophenolic acid protein binding. J Clin Pharmacol 1999 39 : 715 20.
30. Shipkova M, Strassburg CP, Braun F, Streit F, Grone HJ, Armstrong VW, Tukey RH, Oellerich M, Wieland E. Glucuronide and glucoside conjugation of mycophenolic acid by human liver, kidney and intestinal microsomes. Br J Pharmacol 2001 132 : 1027 34.
31. Hesselink DA, Van Hest RM, Mathot RA, Bonthuis F, Weimar W, de Bruin RW, Van Gelder T. Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2. Am J Transplant 2005 5 : 987 94.
32. Van Gelder T, Klupp J, Barten MJ, Christians U, Morris RE. Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid. Ther Drug Monit 2001 23 : 119 28.
33. Cremers S, Schoemaker R, Scholten E, den Hartigh J, Konig-Quartel J, van Kan E, Paul L, de Fijter J. Characterizing the role of enterohepatic recycling in the interactions between mycophenolate mofetil and calcineurin inhibitors in renal transplant patients by pharmacokinetic modelling. Br J Clin Pharmacol 2005 60 : 249 56.
34. Shum B, Dufull SB, Taylor PJ, Tett SE. Population pharmacokinetic analysis of mycophenolic acid in renal transplant recipients following oral administration of mycophenolate mofetil. Br J Clin Pharmacol 2003 56 : 188 97.
35. Le Guellec C, Bourgoin H, Büchler M, Le Meur Y, Lebranchu Y, Marquet P, Paintaud G. Population pharmacokinetics and Bayesian estimation of mycophenolic acid concentrations in stable renal transplant patients. Clin Pharmacokinet 2004 43 : 253 66.
36. Payen S, Zhang D, Maisin A, Popon M, Bensman A, Bouissou F, Loirat C, Gomeni R, Bressolle F, Jacqz-Aigrain E. Population pharmacokinetics of mycophenolic acid in kidney transplant pediatric and adolescent patients. Ther Drug Monit 2005 27 : 378 88.
37. Prémaud A, Le Meur Y, Debord J, Szelag JC, Rousseau A, Hoizey G, Toupance O, Marquet P. Maximum a posteriori Bayesian estimation of mycophenolic acid pharmacokinetics in renal transplant recipients at different postgrafting periods. Ther Drug Monit 2005 27 : 354 61.
38. Staatz CE, Duffull SB, Kiberd B, Fraser AD, Tett SE. Population pharmacokinetics of mycophenolic acid during the first week after renal transplantation. Eur J Clin Pharmacol 2005, July 28, Epub ahead of print.
39. Van Hest RM, Van Gelder T, Vulto AG, Mathot RA. Population pharmacokinetics of mycophenolic acid in renal transplant recipients. Clin Pharmacokinet 2005 44 : 1083 96.
40. Higaki K, Yamashita S, Amidon GL. Time-dependent oral absorption models. J Pharmacokin Pharmacodyn 2001 28 : 109 28.
41. Van Gelder T, Shaw LM. The rationale for and limitations of therapeutic drug monitoring of mycophenolate mofetil in transplantation. Transplantation 2005 80 : S244 S253.
42. Van Gelder T, Meur YL, Shaw LM, Oellerich M, Denofrio D, Holt C, Holt DW, Kaplan B, Kuypers D, Meiser B, Toenshoff B, Mamelok RD. Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther Drug Monit 2006 28 : 145 54.